European CHMP recommends approval of dostarlimab (Jemperli) for recurrent or advanced endometrial cancer

Dostarlimab is an antineoplastic monoclonal antibody indicated as monotherapy for the treatment of adults with recurrent or advanced mismatch repair deficient endometrial cancer that has progressed on or following prior treatment with a platinum‑containing regimen.

European Medicines Agency